Oculis Holding AG, a biopharma company advancing treatments for ophthalmic and neuro-ophthalmic diseases, will present new data at several high-profile scientific forums in September 2025. These include the Ophthalmology Futures Retina Forum, the EURETINA Innovation Spotlight, the 25th European Society of Retina Specialists (EURETINA) Congress, and the Retina Society Annual Congress.
Key Clinical Updates
OCS-01 (for Diabetic Macular Edema, DME)
- Data presented: Subgroup analyses from Stage 1 of the Phase 3 DIAMOND program, focusing on lens status (phakic vs pseudophakic) and prior treatment status (treatment-naïve vs previously treated patients).
- Potential impact: Results highlight OCS-01’s ability to benefit diverse DME patient groups.
- Formulation advantage: OCS-01 is a high-concentration dexamethasone eye drop leveraging OPTIREACH technology to deliver drug directly to the retina via a non-invasive route.
- Paradigm shift: Unlike invasive injections or implants, OCS-01 could offer patients a topical, non-invasive alternative.
- Phase 3 program: DIAMOND-1 and DIAMOND-2 trials are enrolling over 800 patients, with endpoints focused on visual acuity gains and retinal thickness reductions.
Privosegtor (OCS-05, for Acute Optic Neuritis)
- Trial data: Phase 2 ACUITY study results show clinically meaningful visual improvements and neuroprotection.
- Broader potential: May extend to other neuro-ophthalmic and neurological conditions.
- Regulatory status: Orphan drug designation granted by both FDA and EMA.
- Unmet need: No approved neuroprotective therapy currently exists for acute optic neuritis, a condition that often signals multiple sclerosis.
Award Announcement
- The Ramin Tadayoni Award, created by EURETINA in partnership with Oculis, will be presented on September 4, 2025.
- The award recognizes outstanding postgraduate research in retinal disease, honoring the legacy of Prof. Tadayoni, Oculis’ late Chief Scientific Officer.
Presentation Highlights
- Ophthalmology Futures Retina Forum (Sept 3)
- Panel on Diabetic Retinopathy – CEO Riad Sherif, M.D.
- Corporate presentation – Riad Sherif, M.D. - EURETINA Innovation Spotlight (Sept 3)
- Corporate presentation – Sharon Klier, M.D., Chief Development Officer - EURETINA Congress (Sept 4–5)
- Subgroup data from DIAMOND trial – Dr. Patricio Schlottmann & Dr. Veeral Sheth
- ACUITY late-breaking data on Privosegtor – Dr. Sophie Bonnin - Retina Society Annual Congress (Sept 11)
- DIAMOND subgroup data – Dr. Diana Do
Expert Profiles
- Dr. Sophie Bonnin – Deputy Head, Rothschild Foundation Hospital; specialist in retinal and neuro-ophthalmic diseases.
- Dr. Diana Do – Professor of Ophthalmology, Stanford University; author of 200+ publications.
- Dr. Patricio Schlottmann – Director of Research, Charles Ophthalmic Center, Argentina; advisor on retinal disease research.
- Dr. Veeral Sheth – Director of Clinical Trials, University Retina and Macula Associates, U.S.; specialist in retinal vascular disease and AMD.
Disease Context
- Diabetic Macular Edema (DME):
- Leading cause of vision loss in diabetic patients.
- Affects ~37 million people globally today; projected to rise to 53 million by 2040.
- Current treatments are invasive and burdensome. - Acute Optic Neuritis:
- Rare, affects up to 8 in 100,000 people worldwide, often first sign of multiple sclerosis.
- Strong unmet need for therapies that prevent irreversible vision loss.
About Oculis
Oculis is a global biopharmaceutical company developing treatments for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs. Its pipeline includes late-stage assets such as OCS-01 for DME and Privosegtor (OCS-05) for optic neuritis.
